Home Ideas & Research Indexes Hedge Funds Portfolios My tickerspy Newswire
Enter ticker(s) QQQ: 73.54 -0.11%   SPY: 165.62 -0.19%
Quote Spy EXEL NEW Message Board  
Click to close X

Visit a stock's Spy page to see who else is tracking it and who else is talking about it. Spy pages also list institutional holders.


Exelixis (EXEL)

@ 3:09 PM
Click the portfolio to add EXEL:
Close [X]
+ Add EXEL to Portfolio
  
  Last Trade: $4.76 +0.18 (4.04%)
  Volume: 819,243 51% of avg daily volume
       
  Avg Volume: 1,626,294
3-Month Chart (Larger chart w/volume)
Close [X]
1m  3m  6m  1y  2y
  Day's Range: 4.51 - 4.78
  Open: 4.53
  Previous Close: 4.58
  52-wk Range: 4.19 - 6.95
  Market Cap: 841.7M
  P/E: -4.7
  Div Yield: $0.00 (0.00%)
Indexes
Biotechnology Stocks (+1.3%)
Cancer Stocks (+0.7%)
Spy EXEL

? Pro holders
? Member holders
? Items submitted
Additional EXEL resources



Customize Links
To see which Pros and tickerspy members own EXEL Sign up now
Latest EXEL Notes & Links
View: Headlines   |   Message Board   |   Portfolio Notes  

Exelixis Announces First Quarter 2013 Financial Results
EXEL  
Linked by BusinessWire - May 07, 04:15PM from (www.businesswire.com)
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended March 31, 2013. Q1 2013 Highlights and  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Exelixis Announces May 7th Webcast of First Quarter 2013 Financial Results Conference Call
EXEL  
Linked by BusinessWire - April 17, 06:13PM from (www.businesswire.com)
Exelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2013 financial results on Tuesday, May 7, 2013 after the markets  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
EXELIXIS SELECTS SWEDISH ORPHAN BIOVITRUM AB AS COMETRIQ (TM) EUROPEAN DISTRIBUTOR FOR MEDULLARY THYROID CANCER
EXEL  
Linked by GlobeNewswire - February 22, 02:43AM from (globenewswire.com)
Contact:
Charles Butler
Vice President, Investor Relations and Corporate Communications
Exelixis, Inc.
 more ...

Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
EXELIXIS VÄLJER SWEDISH ORPHAN BIOVITRUM AB SOM EUROPEISK DISTRIBUTÖR FÖR COMETRIQ (TM) FÖR MEDULLÄR TYREOIDEACANCER
EXEL  
Linked by GlobeNewswire - February 22, 02:43AM from (globenewswire.com)
Kontakt på Exelixis:
Charles Butler
Vice President, Investor Relations and Corporate Communications
Exelixis, Inc.
 more ...

Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Exelixis Selects Swedish Orphan Biovitrum AB as COMETRIQ™ European Distributor for Medullary Thyroid Cancer
EXEL  
Linked by BusinessWire - February 21, 04:24PM from (www.businesswire.com)
Exelixis, Inc. (NASDAQ:EXEL) and Swedish Orphan Biovitrum (Sobi) (STO: SOBI) today announced that they have entered into  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Exelixis Announces Fourth Quarter and Full Year 2012 Financial Results
EXEL  
Linked by BusinessWire - February 21, 04:18PM from (www.businesswire.com)
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2012. Q4  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Exelixis Announces February 21st Webcast of Fourth Quarter and Full Year 2012 Financial Results Conference Call
EXEL  
Linked by BusinessWire - February 07, 04:56PM from (www.businesswire.com)
Exelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full year 2012 financial results on Thursday, February  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Alexion Pharmaceuticals Among Healthcare's Biggest Movers on October 23, 2012
TECH  REGN  AMRN  ALXN  SHPG  EXEL  BMRN  
Linked by Investopedia Stock Analysis - October 23, 09:19AM from (stocks.investopedia.com)
It's been a bad day for the market after the morning's trading. The Nasdaq has decreased 0.8%; the S&P 500 is down  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
“Orphan” Drugs: Big Profits in Niche Markets
FRX  EXEL  
Linked by InvestingDaily - September 17, 03:43PM from (www.investingdaily.com)
The days when pharmaceutical companies ignored rare diseases because the market was too small are gone. Treating rare diseases  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
An Early Look at 2012 ASCO Biotech Cancer Stocks
BMY  LLY  AMGN  BVTI  CLDX  IMGN  ARIA  MYGN  NKTR  EXEL  PCYC  ONXX  ARQL  GNBT  SGEN  SNSS  ARRY  DNDN  CYCC  GHDX  OPTR  SNTA  ABPI  AVEO  CYTR  GALE  NLNK  
Linked by 24/7 Wall St. - May 18, 07:47AM from (247wallst.com)
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012 annual meeting  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Page 1 2 3 4 5 6 7 8 9 ... 11



Close [X]
Select the external links you'd like on the quote and portfolio pages. We recommend 5 to 6 links. Request a new resource.
Profile/Financials
Yahoo! Profile
Yahoo! Key Stats
MSN Financials

Analysts
Nasdaq Analysts
Yahoo! Estimates
Charts / TA
Clearstation
Google Charts
StockCharts

Subscription
Insiderscore
10k Wizard
CallStreet
Other
Short Interest
SEC Filings
Insiders
Fool CAPS


Request a new resource